StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a sell rating to a hold rating in a research report sent to investors on Tuesday. Other research analysts have also issued research reports about the company. Citigroup raised Editas Medicine from a neutral rating to a buy rating and set a $11.00 target […]
StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a sell rating to a hold rating in a report released on Tuesday. Several other research analysts also recently weighed in on the company. Citigroup upgraded Editas Medicine from a neutral rating to a buy rating and set a $11.00 target price on the […]
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have issued a buy recommendation on the company. The average […]
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned an average recommendation of “Hold” from the thirteen research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation […]
Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) gapped up before the market opened on Wednesday after Truist Financial raised their price target on the stock from $15.00 to $20.00. The stock had previously closed at $9.84, but opened at $10.38. Truist Financial currently has a buy rating on the stock. Editas Medicine shares last […]